Unicycive Therapeutics (NASDAQ:UNCY) Stock Rating Lowered by Wall Street Zen

by · The Cerbat Gem

Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday, Wall Street Zen reports.

Several other research firms also recently weighed in on UNCY. Weiss Ratings restated a “sell (d-)” rating on shares of Unicycive Therapeutics in a research note on Friday, September 4th. HC Wainwright reduced their price objective on shares of Unicycive Therapeutics from $15.00 to $13.00 and set a “buy” rating on the stock in a research report on Tuesday, September 29th. Zacks Research raised shares of Unicycive Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 19th. B. Riley Financial reissued a “buy” rating and issued a $20.00 target price (down from $22.00) on shares of Unicycive Therapeutics in a report on Wednesday, August 12th. Finally, Guggenheim restated a “buy” rating and set a $25.00 target price (down from $37.00) on shares of Unicycive Therapeutics in a research report on Thursday, August 13th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $18.25.

Read Our Latest Stock Analysis on UNCY

Unicycive Therapeutics Stock Performance

UNCY opened at $3.55 on Friday. The stock has a market cap of $98.87 million, a price-to-earnings ratio of -2.03 and a beta of 1.91. The firm’s fifty day moving average is $4.19 and its 200 day moving average is $5.94. Unicycive Therapeutics has a fifty-two week low of $3.33 and a fifty-two week high of $8.74.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of UNCY. Dimensional Fund Advisors LP bought a new stake in Unicycive Therapeutics during the first quarter worth approximately $940,000. Seven Fleet Capital Management LP bought a new stake in shares of Unicycive Therapeutics in the 1st quarter valued at approximately $367,000. Chicago Partners Investment Group LLC lifted its stake in shares of Unicycive Therapeutics by 26.0% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 26,966 shares of the company’s stock valued at $105,000 after purchasing an additional 5,556 shares during the last quarter. Pinnacle Wealth Planning Services Inc. bought a new stake in shares of Unicycive Therapeutics in the 3rd quarter valued at approximately $36,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Unicycive Therapeutics in the 2nd quarter worth approximately $248,000. 40.42% of the stock is owned by hedge funds and other institutional investors.

About Unicycive Therapeutics

(Get Free Report)

Unicycive Therapeutics is a biopharmaceutical company focused on developing treatments for kidney diseases. Its lead program, oxylanthanum carbonate (OLC), is an oral phosphate binder being developed to help manage hyperphosphatemia, or elevated blood phosphate levels, in people with chronic kidney disease, including patients receiving dialysis. The company is also developing UNI-494, an investigational small-molecule therapy for acute kidney injury. These programs reflect Unicycive’s focus on conditions for which treatment options may be limited.

Further Reading